Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions
Hepatocellular Cancer
Interventions
DRUG

Sorafenib

"Dose escalation:~Dose level 1: 200mg of sorafenib daily~Dose level 2: 200mg of sorafenib BID (twice daily)~Dose level 3: 200mg QAM (taken every morning) and 400mg QPM (taken every evening)~Dose level 4: 400mg BID (twice daily)"

Trial Locations (3)

10032

Columbia University Medical Center, New York

90089

University of Southern California, Los Angeles

90095

University of California, Los Angeles, Los Angeles

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

Bayer

INDUSTRY

collaborator

Amgen

INDUSTRY

lead

Columbia University

OTHER